License Agreement with Carnegie Mellon University - Additional Information (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Jul. 12, 2019 |
Dec. 17, 2018 |
Sep. 30, 2018 |
Sep. 30, 2018 |
Sep. 30, 2019 |
|
| Acquired Finite-Lived Intangible Assets [Line Items] | |||||
| Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Shares | 2,829,248 | ||||
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 5,620,000 | ||||
| Stock Issued During Period, Right to Receive, Shares, Share Based Compensation | 5,727,090 | ||||
| Research and development | $ 12,819 | $ 4,273,318 | |||
| License Agreement with Carnegie Mellon University | |||||
| Acquired Finite-Lived Intangible Assets [Line Items] | |||||
| Stock Issued During Period, Right to Receive, Shares | 820,000 | 835,625 | |||
| Stock Issued During Period, Shares, Purchase of Assets | 835,625 | 820,000 | |||
| Research and development | $ 1,046,965 | ||||
| Fully-diluted common stock held (in percent) | 8.20% | ||||
| Funding amount | $ 2,000,000 |
| X | ||||||||||
- Definition Equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. No definition available.
|
| X | ||||||||||
- Definition The first funding amount. No definition available.
|
| X | ||||||||||
- Definition Percentage of fully diluted common stock held by former stock holders, option holders, warrant holders and note holders of legal entity. No definition available.
|
| X | ||||||||||
- Definition The number of shares to be received as a right pursuant to the Exchange ratio. No definition available.
|
| X | ||||||||||
- Definition The number of shares to be received as a right pursuant to the Exchange ratio. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. No definition available.
|
| X | ||||||||||
- Definition Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|